Association of chromosomal locus 8q24 and risk of prostate cancer: A hospital-based study of German patients treated with brachytherapy

Meyer, Andreas; Schürmann, Peter; Ghahremani, Maryam; Kocak, Ertan; Brinkhaus, Maria-Jantje; Bremer, Michael; Karstens, Johann H.; Hagemann, Jörn; Machtens, Stefan; Dörk, Thilo

doi:10.1016/j.urolonc.2008.04.010

« Previous Next »Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 4 , Pages 373-376, July 2009

Association of chromosomal locus 8q24 and risk of prostate cancer: A hospital-based study of German patients treated with brachytherapy

Andreas Meyer, M.D.
- Hannover Prostate Cancer Study Group, Department of Radiation Oncology, Hannover Medical School, Hannover, Germany
Peter Schürmann
- Department of Gynecology, Hannover Medical School, Hannover, Germany
Maryam Ghahremani
- Department of Gynecology, Hannover Medical School, Hannover, Germany
Ertan Kocak
- Department of Gynecology, Hannover Medical School, Hannover, Germany
Maria-Jantje Brinkhaus
- Department of Gynecology, Hannover Medical School, Hannover, Germany
- Department of Pediatrics, Hannover Medical School, Hannover, Germany
Michael Bremer, M.D.
- Hannover Prostate Cancer Study Group, Department of Radiation Oncology, Hannover Medical School, Hannover, Germany
Johann H. Karstens, M.D.
- Hannover Prostate Cancer Study Group, Department of Radiation Oncology, Hannover Medical School, Hannover, Germany
Jörn Hagemann, M.D.
- Department of Urology, Hannover Medical School, Hannover, Germany
Stefan Machtens, M.D.
- Department of Urology, Hannover Medical School, Hannover, Germany
- Present address: Clinics of Urology, Marien-Hospital, Bergisch Gladbach, Germany.
Thilo Dörk, Ph.D.
- Department of Gynecology, Hannover Medical School, Hannover, Germany
- Corresponding author. Tel.: +49-511-532-6075; fax: +49-511-532-6081

Received 23 January 2008; received in revised form 7 April 2008; accepted 8 April 2008. published online 14 July 2008.

Abstract

Background

Genetic susceptibility contributes to the risk of prostate cancer but the underlying genes are largely unknown. Polymorphic loci on chromosome 8q24 have emerged as possible risk factors for breast and prostate cancer from genome-wide association studies.

Objective

We aimed to define the risks associated with two single nucleotide polymorphisms, rs1447295 and rs13281615, in a hospital-based series of prostate cancer patients treated with brachytherapy.

Material and methods

We analyzed genomic DNA samples of 488 prostate cancer cases undergoing brachytherapy at Hannover Medical School, and of 462 male controls from the same location. Genotyping was performed using 5′-exonuclease allelic discrimination assays, and results were evaluated with χ² tests and logistic regression analyses.

Results

We investigated whether rs1447295 and rs13281615 are associated with disease risk in a hospital-based prostate cancer case-control series from Northern Germany. The rare allele of rs1447295 was observed at higher frequency among cases than among hospital-based controls (13.9% vs. 10.2%, P = 0.01), and there was a dose-dependent trend towards a higher prevalence of heterozygous and homozygous carriers among the prostate cancer patients (per allele OR 1.42, 95% CI 1.07; 1.87, P = 0.02). By contrast, the rare allele of rs13281615 did not predispose to prostate cancer (per allele OR 0.84, 95% CI 0.70; 1.00, P = 0.05). The distribution of combined 8q24 genotypes was significantly different between cases and controls (P = 0.01).

Conclusion

Our results corroborate previous reports of 8q24 as a prostate cancer susceptibility locus and provide evidence for rs1447295 as a potentially important genetic marker. Further studies are required to confirm whether the adjacent breast cancer-associated variant rs13281615 may be inversely associated with prostate cancer risk.

Keywords: Prostate cancer susceptibility, Genetic predisposition, Association study, Brachytherapy